PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24647745-2 2014 In rat TAECs, imipramine was biotransformed into N-demethylate and N-oxide by cytochrome P450 (CYP) and flavin-containing monooxygenase (FMO), respectively. Imipramine 14-24 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 78-93 24647745-2 2014 In rat TAECs, imipramine was biotransformed into N-demethylate and N-oxide by cytochrome P450 (CYP) and flavin-containing monooxygenase (FMO), respectively. Imipramine 14-24 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 95-98 11990081-4 2001 The aim of the present study was to investigate the influence of imipramine, amitriptyline and fluoxetine on cytochrome P-450 activity measured by caffeine oxidation in rat liver microsomes. Imipramine 65-75 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 109-125 10401680-0 1999 Imipramine- and mianserin-induced acute cell injury in primary cultured rat hepatocytes: implication of different cytochrome P450 enzymes. Imipramine 0-10 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 114-129 10401680-7 1999 These findings indicated that CYP-mediated metabolic activation was involved in acute cell injury induced by the antidepressants; namely a CYP2D enzyme(s), which is deficient in Dark Agouti rats, and a male specific CYP enzyme(s) were suggested to be responsible for the cytotoxicity of imipramine and mianserin, respectively. Imipramine 287-297 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 30-33 8565792-0 1995 Inhibition and induction of cytochrome P450 isozymes after repetitive administration of imipramine in rats. Imipramine 88-98 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 28-43 8565792-7 1995 These results indicate that imipramine has two actions on the liver CYP system (i.e. as an inhibitor of the CYP2D enzyme and as a phenobarbital-type inducer). Imipramine 28-38 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 68-71 8565792-4 1995 Imipramine pretreatment also resulted in an increase in total CYP content and in formation of a ferrous CYP metabolic intermediate (MI)-complex absorbing at 454 nm. Imipramine 0-10 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 62-65 8565792-4 1995 Imipramine pretreatment also resulted in an increase in total CYP content and in formation of a ferrous CYP metabolic intermediate (MI)-complex absorbing at 454 nm. Imipramine 0-10 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 104-107 1683700-5 1991 Chronic treatment with IMI significantly elevated the concentration of cytochrome P-450 in the liver and had a tendency to increase the concentration of cytochrome b-5. Imipramine 23-26 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 71-87 3368009-4 1988 On the basis of studies in vitro it is concluded that the observed metabolic interaction between carbamazepine and imipramine is due to the competition of the drugs for the active centre of cytochrome P 450 and to a certain qualitative alteration of the enzyme by imipramine as can be deducted from the decrease of carbamazepine binding to the cytochrome. Imipramine 115-125 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 190-206 3225754-7 1988 These data strongly suggest that the hydroxylation pathways of imipramine and desipramine and the demethylation pathways of imipramine and 2-hydroxyimipramine are each sharing the same species of cytochrome P-450. Imipramine 63-73 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 196-212 3225754-7 1988 These data strongly suggest that the hydroxylation pathways of imipramine and desipramine and the demethylation pathways of imipramine and 2-hydroxyimipramine are each sharing the same species of cytochrome P-450. Imipramine 124-134 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 196-212 2234106-0 1990 Alteration of cytochrome P-450 by prolonged administration of imipramine and/or lithium to rats. Imipramine 62-72 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 14-30 2234106-1 1990 The aim of this study was to investigate imipramine-induced alterations of cytochrome P-450 and to determine whether prolonged concomitant administration of imipramine and lithium results in a pharmacokinetic interaction. Imipramine 41-51 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 75-91 2234106-4 1990 The long term treatment with imipramine produced a very complex alteration of cytochrome P-450: imipramine increased the level of the cytochrome, but it decreased the rate of its own aromatic hydroxylation in position 2. Imipramine 29-39 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 78-94 2234106-4 1990 The long term treatment with imipramine produced a very complex alteration of cytochrome P-450: imipramine increased the level of the cytochrome, but it decreased the rate of its own aromatic hydroxylation in position 2. Imipramine 96-106 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 78-94 2234106-10 1990 The preliminary SDS-PAGE analysis of cytochrome P-450 isoenzymes of control and imipramine treated rats showed that the investigated antidepressant markedly intensified a protein band at 50.11 kD while bands at 51.28 kD, 56.20 kD and 56.88 kD were less intensive. Imipramine 80-90 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 37-53 2234106-11 1990 These results indicate that the alteration of cytochrome P-450 by imipramine treatment is not only of quantitative but also of qualitative character. Imipramine 66-76 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 46-62 2234106-13 1990 Lithium given jointly with imipramine reduced imipramine-induced elevation of cytochrome P-450. Imipramine 27-37 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 78-94 2234106-13 1990 Lithium given jointly with imipramine reduced imipramine-induced elevation of cytochrome P-450. Imipramine 46-56 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 78-94 3027154-4 1986 When imipramine is given 30 min before CCl4, it inhibits in part the CCl4-induced lipid peroxidation and the covalent interactions of reactive metabolites with microsomal lipids or proteins and partially prevents CCl4-induced cytochrome P-450 destruction, but not glucose 6 phosphatase activity depression. Imipramine 5-15 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 226-242 3027154-6 1986 Early preventive effects of imipramine on cytochrome P-450, might be attributed to inhibition of covalent interactions of reactive metabolites. Imipramine 28-38 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 42-58 32748256-1 2020 BACKGROUND: The aim of our research was to determine the effects of chronic treatment with the atypical antidepressant agomelatine on the expression and activity of liver cytochrome P450 (CYP) in the chronic mild stress (CMS) model of depression, and to compare the results with those obtained for the first-generation antidepressant imipramine. Imipramine 334-344 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 171-186 32748256-1 2020 BACKGROUND: The aim of our research was to determine the effects of chronic treatment with the atypical antidepressant agomelatine on the expression and activity of liver cytochrome P450 (CYP) in the chronic mild stress (CMS) model of depression, and to compare the results with those obtained for the first-generation antidepressant imipramine. Imipramine 334-344 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 188-191 32748256-5 2020 RESULTS: Agomelatine and imipramine produced different broad-spectrum effects on cytochrome P450. Imipramine 25-35 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 81-96 32748256-10 2020 CONCLUSION: We conclude the following: (1) the effects of agomelatine and imipramine on cytochrome P450 are different and involve both central and peripheral regulatory mechanisms, which implicates the possibility of drug-drug interactions; (2) CMS influences the effects of antidepressants on cytochrome P450 expression, but does not change appreciably their effects on the enzyme activity. Imipramine 74-84 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 88-103 32748256-10 2020 CONCLUSION: We conclude the following: (1) the effects of agomelatine and imipramine on cytochrome P450 are different and involve both central and peripheral regulatory mechanisms, which implicates the possibility of drug-drug interactions; (2) CMS influences the effects of antidepressants on cytochrome P450 expression, but does not change appreciably their effects on the enzyme activity. Imipramine 74-84 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 294-309